Cancer BiologybioRxivPreprint
Co-targeting MERTK and EGFR with a Bispecific Antibody Overcomes Drug Resistance Across Mutations in Exons 19, 20, and 21
Suvendu Giri, Boobash-Raj Selvadurai, Arturo Simoni Nieves…·Yosef Yarden
This study develops a bispecific antibody targeting MERTK and EGFR to overcome drug resistance in lung cancer with mutations in exons 19, 20, and 21.
DOI 10.1101/2025.10.16.681972